|
|
Office Locations:
|
150 N Riverside Plaza, Suite 5100
Chicago, IL 60606
Phone: 312-506-5600
Fax: 312-506-5601
| | |
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
Formed in 2002, Linden is a healthcare and life sciences private equity firm that builds value in mature businesses. Linden's investment strategy is to purchase controlling equity interests in privately held companies and non-core businesses that can benefit from strategic redirection, operational improvements, acquisitions and additions to the management team. Linden invests primarily in leveraged buyouts or other late-stage transactions where it can be the lead investor or otherwise have significant governance influence. Linden does not make venture capital investments. Currently, Linden has raised over $6 billion in limited partner commitments; augmented by capital provided by their Limited Partners for larger transactions. To invest in mature companies of all sizes, Linden formed an alliance with Madison Dearborn Partners (see profile) to pursue large healthcare and life science buyout transactions (transactions requiring more than $50 million in private equity capital). Linden pursues smaller transactions (requiring less than $50 million in private equity capital) using its own funds.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
